Recent advancements in gene therapy for sickle cell disease and β-thalassemia
Open Access
- 27 September 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Hematology
- Vol. 3, 1468952
Abstract
β-hemoglobinopathies, including sickle cell disease (SCD) and β-thalassemia, are prevalent monogenic disorders causing abnormal hemoglobin structure or production that affect millions globally. Current available therapies for SCD and β-thalassemia are primarily symptomatic treatments and allogeneic hematopoietic stem cell transplant (HSCT). Allo-HSCT is the only curative treatment, which has limitations. Gene therapy using genetically modified hematopoietic stem cells (HSCs) holds promise to be an effective curative therapy. Recently approved ex vivo genetically modified HSC-based therapeutics (CASGEVY, LYFGENIA, ZYNTEGLO) have shown remarkable and durable therapeutic benefits for SCD and β-Thalassemia. In this review article, we discuss the current genetic approaches and innovative strategies to ensure safe and effective gene therapy for SCD and β-thalassemia and summarize findings from completed and ongoing clinical trials. We also discuss prospects and challenges of in vivo gene editing with CRISPR/Cas technology for SCD and beta-thalassemia that may simplify manufacturing and treatment process. In vivo gene therapy may minimize the risks associated with ex vivo gene therapy and may overcome multiple barriers associated with complex gene therapy products for wider patient access, especially in developing regions of the world where these diseases are highly prevalent.Keywords
This publication has 179 references indexed in Scilit:
- Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cellsHuman Genetics, 2023
- Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 studyAmerican Journal of Hematology, 2022
- Hematopoietic stem cell transplantation for sickle cell disease: Progress and challengesPediatric Blood & Cancer, 2018
- A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell DiseaseStem Cells Translational Medicine, 2017
- Development and Applications of CRISPR-Cas9 for Genome EngineeringCell, 2014
- Sickle Cell Disease in AfricaAmerican Journal of Preventive Medicine, 2011
- Position-independent, high-level expression of the human β-globin gene in transgenic miceCell, 1987
- β+ Thalassemia: Aberrant splicing results from a single point mutation in an intronCell, 1981
- Ligand-induced conformational dependence of hemoglobin in sickling interactionsJournal of Molecular Biology, 1971
- PECULIAR ELONGATED AND SICKLE-SHAPED RED BLOOD CORPUSCLES IN A CASE OF SEVERE ANEMIAArchives of internal medicine (1960), 1910